A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Topic / Pathology
- JAK i
- observational
Objectives
The purpose of this study is to learn about the safety and effects of Abrocitinib in the real-life clinical setting given for the treatment of moderate to severe atopic dermatitis. Atopic dermatitis, or AD, is a long-lasting disease that causes inflammation, redness, and irritation of the skin.
All participants in this study will receive Abrocitinib as a tablet once daily. They can take Abrocitinib and use medicated topical treatment for AD at the same time.
We will examine the experiences of patients receiving the study medicine. This will help us determine if the study medicine is safe and helps in treating AD.
Participants will take part in this study for 24 months. During this time, they will visit the study clinic about 5 times (about 1 time every 4 to 6 months).
Sponsor
Pfizer
Investigator
Hôpital Begin, Saint Mandé
Critères d'inclusion
This study is seeking participant who are older than 18 years with moderate-to-severe chronic AD.
Critères de non-inclusion
Participants must have no underlying medical conditions that prevent them from taking Abrocitinib.
Status
Ongoing
